RA Capital Management, AN Venture Partners and UTEC led a $14m round in Pahr Therapeutics.

RA Capital Management, AN Venture Partners, and UTEC, venture capital firms, led a $14m round in Pahr Therapeutics, a clinical-stage company focused on developing novel mechanisms for the treatment of pulmonary arterial hypertension. "I am excited to work with RA Capital Management, AN Venture Partners, and UTEC to bring much needed new therapies to PAH patients. Having global investors support the company is inspiring for us, and we look forward to advancing into clinical studies early next year," Yoshikazu Nakaoka, Pahr Therapeutics Co-Founder.